| |
 |
 |
Powering tomorrow's biopharmaceutical companies
CBI's extensive knowledge of the biopharmaceutical industry, proven investment expertise, market leadership, strategic relationships, and network of academic and industry contacts - all come together to successfully create a flourishing portfolio of biotechnology companies. These companies generate value for their shareholders and are rapidly becoming leaders in their respective fields: from cancer therapeutics and novel treatments for autoimmune diseases, through chronic wound management and innovative drugs for brain disorders, to selective drug targeting and delivery for central nervous system diseases.
Our unique investment strategy together with our strong resources assists our portfolio companies through the challenges of product and business development. We help recruit management executives and advisors, identify complementary technologies and products, negotiate agreements, develop business strategies, and ensure successful follow-on financings.
| Company |
Holdings |
Field |
Stage |
| Polyheal |
38% |
Wound management |
Market approved |
| MediWound |
52% |
Burn & wound management |
Registration |
| D-Pharm |
46% |
Ischemic stroke |
Phase III |
| Andromeda |
84% |
Type 1 Diabetes |
Phase III |
| Gamida Cell |
20% |
Cancer |
Phase III |
| CureTech |
37% |
Cancer |
Phase II |
| BioCancell |
15% |
Cancer |
Phase II |
| Avraham |
16% |
Alzheimer's disease |
Phase II |
| Biokine |
31% |
Cancer |
Phase II |
| TransPharma |
12% |
Osteoporosis |
Phase II |
| Aposense |
4% |
Cancer |
Phase II |
| Thrombotech |
42% |
Ischemic stroke |
Phase II |
| BrainTact |
38% |
CNS |
Pre-clinical |
| Protab |
15% |
Autoimmune |
Pre-clinical |
| BioControl |
3% |
Cardiology |
Pivotal studies |
| Clal Life Sciences |
100% |
GMP facility |
|
| Campus Bio |
100% |
Drug
Development |
|
|
|
|
